A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM

This study is designed to test how well once-weekly MET097 (an ultra-long-acting GLP-1 receptor agonist) works to treat adults with obesity or overweight and type 2 diabetes mellitus (T2DM) compared to placebo. MET097 or placebo will be administered to individuals via subcutaneous injection once weekly for 28 weeks. If an individual is randomly assigned to MET097 they will receive one of four different dose regimens.

Inclusion Criteria: * BMI ≥27.0 kg/m2 to ≤50.0 kg/m2 at screening * Type 2 diabetes mellitus (\*T2DM) for at least 3 months before screening * Glycated hemoglobin (HbA1c) value between ≥7.0% (53.0 mmol/mol) and ≤10.5% (91.3 mmol/mol) at Screening and treated with stable therapy for at least 30 days prior to Screening/Visit 1 (diet and exercise alone or in combination with metformin monotherapy and/or SGLT-2) * Stable body weight (increase or decrease ≤5 kg) within 3 months prior to screening Exclusion Criteria: * Female who is lactating or who is pregnant * Estimated glomerular filtration rate (eGFR) \